Most systemic reactogenicity symptoms were mild: amongst participants randomized to ALVAC + gp120/MF59, 6.3% (2/32) reported moderate malaise and/or fatigue, 12.5% (4/32) myalgia, and 3.1% (1/32) arthralgia. The gene discussed is ITIH4; the disease is Myalgia.